Bing

SEARCH HISTORY

Pfizer (NYSE:PFE) recently announced its decision to acquire two meningitis vaccines, Nimenrix and Mencevax, from GlaxoSmithKline (GSK) for $130 million. [1] Both vaccines are approved for commercial sales and the move builds upon Pfizer’s last …
Trefis · 7/1/2015
vaccines
The stock held beta value of 0.59, while return on equity ratio was 11.20%. Can Anthem, Inc. make its way to investors watch list? Find Out Here Pfizer Inc. (NYSE:PFE), Portola Pharmaceuticals (PTLA) and …
streetwisereport.com · 6/23/2015
Pfizer Inc
Pfizer Inc. (PFE - Analyst Report) entered into an agreement with GlaxoSmithKline (GSK - Analyst Report) under which it will acquire the latter’s quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, in a deal valued at about $130 million (€115 ...
ZACKS · 6/23/2015
Meningitis Vaccines
More from Bing News
NAVB closed Thursday's trading at $1.68, up 3.70%. In after-hours, the stock was up 4.76% at $1.76. Pfizer Inc.'s (PFE) new drug application for XELJANZ 11 mg once daily modified release tablets for the treatment of moderate to severe rheumatoid arthritis ...
NASDAQ · 7/2/2015
The board of directors of Pfizer Inc. today declared a 28-cent third-quarter 2015 dividend on the company’s common stock, payable September 2, 2015, to shareholders of record at the close of business on August 7, 2015. The third-quarter 2015 cash ...
Financial Content · 6/25/2015
dividend
Parexel stock hit an all-time high of 72.69 Tuesday ... particularly given uncertainty regarding the profitability / sizing of the Pfizer (NYSE:PFE) relationship (update to come over next 12 months)." Pfizer is one of …
Investors Business Daily · ByAmy Reeves · 6/23/2015
Pfizer (NYSE:PFE) has potential upside of 8.2% based on a current price of $34.46 and analysts' consensus price target of $37.29. The stock should find initial support at its 50-day moving average (MA) of $34.37 and further support at its 200-day MA of …
Financial News Network Online · ByMallory Stone · 6/22/2015
Click to get this free report GLYCOMIMETICS (GLYC): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research Personal Investing Ideas & Strategies Finance Trading
Yahoo Finance · 6/24/2015
While Glaxo carries a Zacks Rank #5 (Strong Sell), Pfizer is a Zacks Rank #3 (Hold) stock. Gilead Sciences Inc. GILD is a better-ranked stock in the health care sector carrying a Zacks Rank #1 (Strong Buy). Want the latest recommendations from Zacks ...
Yahoo News · 6/26/2015
As AQR is a quant hedge fund, that means these aren’t discretionary stock picks. AQR’s mathematical algorithms have been sending “undervalued” signals for these stocks. Apple and Pfizer have consistently …
INSIDER MONKEY · 6/22/2015
hedge funds

Pfizer

Pfizer, Inc. is an American multinational pharmaceutical corporation headquartered in New York City, New York, with its research headquarter…
Pfizer, Inc. is an American multinational pharmaceutical corporation headquartered in New York City, New York, with its research headquarters in Groton, Connecticut. It is among one of the world's largest pharmaceutical companies by revenues.
Data from: Wikipedia